Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults

被引：0
|
作者：
Nils von Hentig
Brenda Dauer
Annette Haberl
Stefan Klauke
Thomas Lutz
Schlomo Staszewski
Sebastian Harder
机构：
[1] Johann Wolfgang Goethe University,Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology
[2] JohannWolfgang Goethe University Hospital Frankfurt,Medical HIV
[3] Infektiologicum Frankfurt,Treatment and Research Unit
来源：
European Journal of Clinical Pharmacology | 2007年 / 63卷
关键词：
HAART; Drug-drug interaction; TDM; Atazanavir; Tenofovir-DF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women
    Conradie, F.
    Zorrilla, C.
    Josipovic, D.
    Botes, M.
    Osiyemi, O.
    Vandeloise, E.
    Eley, T.
    Child, M.
    Bertz, R.
    Hu, W.
    Wirtz, V.
    McGrath, D.
    HIV MEDICINE, 2011, 12 (09) : 570 - 579
  • [42] Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir - Response
    Khanlou, H
    Louie, S
    Farthing, C
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (03) : 394 - 394
  • [43] Sialolithiasis in an HIV-1-infected patient treated with atazanavir/ritonavir monotherapy
    Le, Minh P.
    Stitou, Hind
    Soulie, Cathia
    Katlama, Christine
    Peytavin, Gilles
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (03) : 727 - 729
  • [44] Population pharmacokinetic models for ritonavir boosted atazanavir and tenofovir in highly pretreated HIV infected patients.
    Taburet, A
    Barrail-Tran, A
    Mentré, F
    Piketty, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P47 - P47
  • [45] Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients
    Jansen, A.
    Colbers, E. P. H.
    van der Ven, A. J. A. M.
    Richter, C.
    Rockstroh, J. K.
    Wasmuth, J. C.
    van Luin, M.
    Burger, D. M.
    HIV MEDICINE, 2013, 14 (07) : 449 - 452
  • [46] Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection
    Nishijima, Takeshi
    Shimbo, Takuro
    Komatsu, Hirokazu
    Hamada, Yohei
    Gatanaga, Hiroyuki
    Kikuchi, Yoshimi
    Oka, Shinichi
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (05) : 1385 - 1389
  • [47] The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
    van Heeswijk, RPG
    Veldkamp, AI
    Hoetelmans, RMW
    Mulder, JW
    Schreij, G
    Hsu, A
    Lange, JMA
    Beijnen, JH
    Meenhorst, PL
    AIDS, 1999, 13 (14) : F95 - F99
  • [48] Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients
    Squires, Kathleen E.
    Young, Benjamin
    DeJesus, Edwin
    Bellos, Nicholaos
    Murphy, Daniel
    Zhao, Henry H.
    Patel, Lisa G.
    Ross, Lisa L.
    Wannamaker, Paul G.
    Shaefer, Mark S.
    AIDS, 2010, 24 (13) : 2019 - 2027
  • [49] Population pharmacokinetics (PK) of ritonavir (RTV)-boosted atazanavir (ATV) in HIV-infected and healthy individuals
    Dickinson, L.
    Aarons, L.
    Back, D.
    Waters, L.
    Else, L.
    Khoo, S.
    Pozniak, A.
    Boffito, M.
    HIV MEDICINE, 2009, 10 : 51 - 52
  • [50] Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected Patients
    Ross, Lisa L.
    Weinberg, Winkler G.
    DeJesus, Edwin
    Fischl, Margaret A.
    Horton, Joseph H.
    Pappa, Keith A.
    Lancaster, C. Tracey
    Pakes, Gary E.
    Smith, Kimberly Y.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2010, 26 (04) : 407 - 417
12345